At EMSOS 2013, 57357 to share assessment of drug related heart disease in Ewing Sarcoma patients and how to prevent it 57357 is leading the way for improving protocols and patients’ outcomes

A 57357’s group of researchers is participating in the 2013 European Musclo Skeletal Oncology Society (EMSOS) in Gothenburg, Sweden on May, 29, 2013 with an oral presentation .Their findings relate to the incidence , severity, and pattern of cardio toxicity (heart disease) in patients with Ewing’s Sarcoma, due to the effect of a chemotherapy drug, Doxorubibin, or radiotherapy on the chest that may affect the heart. The group, including pediatric oncologists, Dr. Manal Zamzam and Dr.Emad Moussa, cardiology consultant, Dr. Zeinab Salah and clinical research specialist, Ranin Soliman, found that since the start of operations at Hospital 57357 in 2007 till December 2011, out of the 149 Ewing’s Sarcoma patients analyzed for toxicity, 39 patients showed impaired heart functions (26%). Patients were tracked to monitor toxicity by the end of 2012, ranging from one to five years follow-up.

While 44% of patients developed heart disease during protocol treatment (acute onset), 36% developed cardio toxicity within 1 year from end of treatment, and 20% developed heart disease after 1 year from end of treatment (late onset).Based on the above mentioned findings, 57357’s research team will start prospective randomized Clinical Trial for early detection of cardio toxicity. Also, patients will be randomized to receive propylactic drugs to prevent the development of a heart disease. This way we can decrease the risk of heart disease in the future and improve patients’ toxicities from effect of chemotherapy. Hospital 57357’s mandate is and will always be to improve all its patients outcomes not only with respect to curing them from the disease but most importantly increasing their chances of a better healthy life in the future.

It is noteworthy that participation expenses in the conference are partly funded by Egypt Cancer Network 57357(ECN), a US based tax deductible nonprofit with the mission of providing resources to Egyptian Hospitals and non-profit organizations focused on cancer among which hospital 57357, in the areas of patient care, scientific advancement and education.ECN has been established and is being sustained thanks to the generosity of hundreds of Egyptian Americans eager to be of service to their motherland

Ewing’s sarcoma is a rare disease in which cancer cells are found in the bone or in soft tissues. Ewing’s sarcoma is more common in males and occurs mostly between 10 and 20 years of age. It represents 16% of primary bone sarcomas.